Report Description Table of Contents Where Is the Gastric Cancer Therapeutics Market Headed as Biomarker-Based Care Expands? The Global Gastric Cancer Therapeutics Market was valued at USD 5.15 billion in 2025 and is projected to reach USD 10.56 billion by 2032, expanding at a CAGR of 10.85% during 2026–2032, according to Strategic Market Research. Gastric Cancer Therapeutics Market refers to the global market for drugs and therapies used for the treatment of gastric cancer (stomach cancer). It includes chemotherapy, targeted therapies, immune checkpoint inhibitors, antibody-drug conjugates, and other novel therapeutics aimed at improving survival outcomes and expanding treatment options for patients with gastric malignancies. Gastric cancer remains one of the major global oncology challenges, with approximately 968,784 new stomach cancer cases and 660,175 deaths reported globally, making it the fifth most frequently diagnosed cancer worldwide. The disease burden is concentrated in East Asia, particularly China, Japan, and South Korea. Surgical procedures such as endoscopic resection and gastrectomy remain central for early-stage disease, while advanced gastric cancers are primarily managed through drug-based approaches. Chemotherapy represents the leading therapy segment, supported by continued use of fluoropyrimidine- and platinum-based regimens in first-line and combination treatments. Meanwhile, immunotherapy is the fastest-growing segment, driven by increasing adoption of immune checkpoint inhibitors and combination therapies. Approximately 1 million annual gastric cancer cases, nearly 900,000 patients are diagnosed, with around 650,000 requiring systemic therapy. Approximately 520,000 patients are considered eligible for branded therapeutics, while the currently treated population is estimated at 420,000–450,000 patients annually. Leading marketed therapies include Keytruda (pembrolizumab) by Merck, Opdivo (nivolumab) by Bristol Myers Squibb, Enhertu (trastuzumab deruxtecan) by AstraZeneca and Daiichi Sankyo, and HER2-directed therapies from Roche. Emerging products such as bemarituzumab and zanidatamab are expanding options for molecularly selected patient groups. Overall, the Gastric Cancer Therapeutics Market is shifting from conventional chemotherapy-based management toward personalized, biomarker-driven treatment strategies. Future growth will be influenced by increasing adoption of immunotherapy combinations, expansion of targeted therapies, improved cancer screening programs, and greater availability of molecular testing. Which Gastric Cancer Treatment Segments Lead Today—and Which Are Gaining Ground? By Therapy Type Leading Therapy Segment: Chemotherapy – The Established Treatment Backbone for Gastric Cancer Chemotherapy represents the leading therapeutic segment in the Gastric Cancer Therapeutics Market, contributing nearly 34% of total market revenue, valued at approximately USD 1.75 billion in 2025. The segment is expected to grow at a CAGR of 7.85% during 2026–2032, supported by its continued use across early-stage, locally advanced, and metastatic gastric cancer treatment pathways. Chemotherapy remains essential for tumor reduction before surgery, elimination of residual cancer cells after resection, and disease control in advanced gastric cancer cases. Fastest-Growing Therapy Segment: Immunotherapy – Accelerating Shift Toward Immune-Based Cancer Control Immunotherapy is projected to be the fastest-expanding therapy segment in the Gastric Cancer Therapeutics Market, capturing nearly 28% share, equivalent to USD 1.44 billion in 2025 revenue, and is anticipated to grow at a CAGR of 15.10% during 2026–2032. The segment growth is driven by increasing adoption of immune checkpoint inhibitors, particularly PD-1/PD-L1 targeted therapies, which enhance immune system activity against gastric cancer cells. Nivolumab and pembrolizumab are increasingly integrated into advanced gastric cancer treatment protocols, often in combination with chemotherapy or targeted therapies. Emerging approaches, including CLDN18.2-directed cellular therapies and bispecific antibodies, are further expanding the immunotherapy pipeline. By Drug Class Leading Drug Class Segment: Cytotoxic Agents – Maintaining High Clinical Utilization Cytotoxic agents remain the dominant drug class segment in the Gastric Cancer Therapeutics Market, accounting for approximately 38% share, equivalent to USD 1.96 billion in 2025 revenue, and are expected to expand at a CAGR of 7.65% during 2026–2032. These agents continue to form the core of systemic chemotherapy approaches used in advanced, metastatic, and perioperative gastric cancer treatment, with fluoropyrimidines, platinum compounds, taxanes, and topoisomerase inhibitors widely incorporated into combination regimens. Their role is further strengthened through integration with targeted therapies, immunotherapies, and antibody-drug conjugates to improve treatment outcomes. Fastest-Growing Drug Class Segment: PD-1/PD-L1 Immune Checkpoint Inhibitors – Expanding Precision Oncology Adoption PD-1/PD-L1 immune checkpoint inhibitors represent the fastest-growing drug class segment in the Gastric Cancer Therapeutics Market, accounting for approximately 22% share, valued at around USD 1.13 billion in 2025, and are expected to expand at a CAGR of 16.25% during 2026–2032. These therapies enhance anti-tumor immunity by blocking PD-1/PD-L1 signaling pathways, which enables activated T-cells to recognize and attack gastric cancer cells. Increasing adoption in advanced gastric and gastroesophageal junction cancers, supported by biomarker-based patient selection such as PD-L1 CPS and MSI-H/dMMR status, is driving market expansion. By Disease Indication Leading Disease Indication Segment: Gastric Adenocarcinoma and Gastroesophageal Junction Cancer – Dominating Treatment Demand Gastric adenocarcinoma and gastroesophageal junction (GEJ) cancer represent the dominant disease indication segment within the Gastric Cancer Therapeutics Market, accounting for approximately 86% share, equivalent to USD 4.43 billion in 2025 revenue, with a projected CAGR of 10.95% during 2026–2032. Growth in this segment is driven by increasing adoption of stage-specific treatment approaches, including surgery, chemotherapy, targeted therapies, and biomarker-guided immunotherapies. The therapeutic landscape is increasingly shaped by molecular profiling of HER2, PD-L1, MSI/MMR, and Claudin 18.2 biomarkers, enabling personalized treatment selection for localized, advanced, and metastatic gastric cancer patients. Fastest-Growing Disease Indication Segment: Gastric Neuroendocrine Tumors (gNETs) – Emerging Targeted Treatment Opportunity Gastric neuroendocrine tumors (gNETs) represent a specialized segment within the Gastric Cancer Therapeutics Market, accounting for approximately 5% share, equivalent to USD 0.26 billion in 2025 revenue, and are expected to grow at a CAGR of 9.40% during 2026–2032. These tumors arise from hormone-producing enterochromaffin-like (ECL) cells in the stomach and require differentiated therapeutic approaches compared with conventional gastric adenocarcinoma. Treatment strategies vary by tumor type, with surveillance and endoscopic management used for Type 1 tumors, hormone-control therapies for Type 2 tumors, and surgery, chemotherapy, or targeted therapies for aggressive Type 3 tumors. By Route of Administration Leading Route of Administration Segment: Intravenous Therapies – Preferred Delivery Route for Advanced Treatments Intravenous (IV) therapies represent the leading route of administration segment in the Gastric Cancer Therapeutics Market, accounting for approximately 72% share, equivalent to USD 3.71 billion in 2025 revenue, and are expected to expand at a CAGR of 10.25% during 2026–2032. The segment growth is supported by the widespread use of IV-administered chemotherapy, targeted therapies, and immune checkpoint inhibitors that enable rapid systemic drug delivery for advanced and metastatic gastric cancer management. IV formulations remain essential for delivering cytotoxic agents, biologics, and supportive treatments where oral administration is limited. Fastest-Growing Route of Administration Segment: Oral Therapies – Supporting Outpatient Cancer Management Oral therapies represent the fastest-growing administration route, accounting for approximately 28% share, generating USD 1.44 billion in 2025 revenue, and are projected to expand at a CAGR of 12.35% during 2026–2032. Growth is supported by increasing availability of oral targeted medicines, improved patient convenience, and the expansion of outpatient cancer treatment models. Oral therapies allow greater flexibility in long-term treatment management, particularly for maintenance and targeted therapy approaches. By End User Leading End User Segment: Hospitals and Comprehensive Cancer Centers – Core Treatment Infrastructure Hospitals and comprehensive cancer centers represent the largest end-user segment, accounting for approximately 78% share, equivalent to USD 4.02 billion in 2025 revenue, with a projected CAGR of 10.45% during 2026–2032. These facilities dominate because gastric cancer treatment often requires multidisciplinary care involving oncology, surgery, pathology, radiology, and molecular diagnostics. Advanced therapies such as immunotherapy and targeted treatments are primarily initiated and monitored within specialized hospital settings. Fastest-Growing End User Segment: Specialty Oncology Clinics – Increasing Outpatient Treatment Adoption Specialty oncology clinics represent the fastest-growing end-user segment, accounting for approximately 17% share, equivalent to USD 0.88 billion in 2025 revenue, and are projected to expand at a CAGR of 12.60% during 2026–2032. Growth is supported by the increasing shift toward outpatient cancer management, rising availability of infusion centers, and greater adoption of targeted and immune-based therapies requiring regular monitoring rather than prolonged hospitalization. By Geography Leading and Fastest-Growing Regional Segment: Asia-Pacific – Largest Patient Pool and Disease Burden Asia-Pacific Gastric Cancer Therapeutics Market represents the largest regional segment, capturing nearly 38% of global revenue, valued at approximately USD 1.96 billion in 2025. The region’s dominance is supported by the high prevalence of gastric cancer, increasing diagnosis rates, expanding access to targeted and immunotherapy treatments, and rising oncology healthcare investments across major markets such as China, Japan, and South Korea. The regional market is expected to expand at a CAGR of 12.85% during 2026–2032. Who Is Shaping the Next Phase of Gastric Cancer Treatment? Merck & Co. – Advancing Immunotherapy Through Keytruda (Pembrolizumab) Merck & Co. is one of the leading players in gastric cancer therapeutics, primarily driven by its immune checkpoint inhibitor Keytruda (pembrolizumab). The therapy targets the PD-1 immune checkpoint pathway and has become an important treatment option for selected patients with advanced gastric and gastroesophageal junction cancers, particularly those with specific biomarker profiles. Keytruda is increasingly used in combination with chemotherapy and other targeted approaches to improve treatment outcomes in advanced disease. Merck’s oncology portfolio has a significant global presence, with Keytruda generating approximately USD 31.68 billion in worldwide sales in 2025, supported by broad adoption across multiple cancer indications, including gastric cancer. The company continues to expand its immuno-oncology research programs through combination trials evaluating checkpoint inhibitors with chemotherapy, targeted therapies, and emerging cancer treatments. Bristol Myers Squibb – Strengthening Gastric Cancer Immunotherapy With Opdivo Bristol Myers Squibb (BMS) is another major player in gastric cancer treatment through Opdivo (nivolumab), a PD-1 inhibitor used in advanced gastric and gastroesophageal junction cancers. Opdivo has contributed to the expansion of immunotherapy-based treatment strategies by providing an alternative checkpoint inhibition approach, particularly in combination regimens. The company focuses on expanding the role of immunotherapy across gastrointestinal cancers through clinical development programs and combination treatment strategies. Opdivo has demonstrated broad oncology adoption, with approvals spanning multiple tumor types, including stomach and esophageal cancers. BMS reported continued demand growth for Opdivo, supported by additional indication launches and increased utilization across cancer settings. Beyond the Leaders: More Companies Expanding Gastric Cancer Treatment Options AstraZeneca & Daiichi Sankyo – Developing HER2-targeted antibody-drug conjugate Enhertu (trastuzumab deruxtecan) for HER2-expressing gastric and gastroesophageal cancers; the therapy represents a major advancement in targeted cancer treatment. Enhertu generated approximately USD 4.98 billion in combined global sales during FY2025, reflecting strong adoption across oncology indications. F. Hoffmann-La Roche – Strengthening HER2-directed gastric cancer treatment through Herceptin (trastuzumab) and related HER2-targeted strategies, supporting biomarker-driven treatment approaches. Astellas Pharma – Expanding precision oncology through Vyloy (zolbetuximab), a Claudin 18.2-targeted therapy designed for patients with CLDN18.2-positive gastric and GEJ cancers. Amgen – Developing targeted biologic therapies such as bemarituzumab, an FGFR2b-directed therapy aimed at patients with FGFR2b-positive gastric cancer. Eli Lilly – Participating in gastric cancer treatment through targeted oncology medicines, including anti-angiogenic therapies such as ramucirumab (Cyramza), which is used in advanced gastric cancer treatment. Pfizer – Expanding oncology capabilities through antibody-drug conjugates and targeted cancer platforms following its acquisition of Seagen, supporting future gastric cancer pipeline opportunities. BeiGene – Developing immuno-oncology solutions including tislelizumab, a PD-1 inhibitor evaluated in gastric and gastroesophageal cancers. Zymeworks – Advancing HER2-targeted bispecific antibody approaches, including zanidatamab, designed for HER2-positive gastric and GEJ cancers. Analyst View: Biomarker Selection Is Shifting Treatment Value The gastric cancer therapeutics market is undergoing a major transition from broad chemotherapy-based treatment toward biomarker-driven precision oncology. The increasing use of molecular profiling is enabling clinicians to identify patients who may benefit from HER2-targeted therapies, immune checkpoint inhibitors, antibody-drug conjugates, and emerging Claudin 18.2 or FGFR2b-directed treatments. The next phase of market development is expected to be shaped by combination therapies, improved patient selection, and the integration of advanced diagnostics with therapeutic decision-making. Companies that can successfully develop targeted treatments with meaningful clinical benefits are creating new opportunities across the evolving gastric cancer care ecosystem. Gastric Cancer Therapeutics Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 5.15 Billion Revenue Forecast in 2032 USD 10.56 Billion Overall Growth Rate CAGR of 10.85% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Billion, CAGR (2026 – 2032) Segmentation By Therapy Type, By Drug Class, By Disease Indication, By Route of Administration, By End User, By Geography By Therapy Type Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Supportive Care By Drug Class Cytotoxic Agents, HER2-Targeted Therapies and Antibody-Drug Conjugates (ADCs), PD-1/PD-L1 Immune Checkpoint Inhibitors, VEGF, FGFR2, Claudin 18.2, and Other Targeted Agents By Disease Indication Gastric Adenocarcinoma and Gastroesophageal Junction (GEJ) Cancer, Gastrointestinal Stromal Tumors (GISTs), Gastric Neuroendocrine Tumors (gNETs) and Other Rare Gastric Tumors By Route of Administration Intravenous (IV) Therapies, Oral Therapies By End User Hospitals and Comprehensive Cancer Centers, Specialty Oncology Clinics, Research Institutes and Other Healthcare Facilities By Geography Asia-Pacific, North America, Europe, Latin America, Middle East & Africa Market Drivers Increasing adoption of immunotherapy combinations, expansion of targeted therapies, improved cancer screening programs, and greater availability of molecular testing Customization Option Available upon request Frequently Asked Question About This Report Q1. What is the size and growth outlook of this market? A1. The global market was valued at USD 5.15 billion in 2025 and is projected to reach USD 10.56 billion by 2032, expanding at a CAGR of 10.85% during 2026–2032. Q2. What factors are driving growth in this market? A2. Growth is supported by a global disease burden of approximately 968,784 new cases, wider molecular testing, and increasing use of immunotherapy combinations. Expanding HER2-, PD-1/PD-L1-, Claudin 18.2-, and FGFR2b-targeted treatments is also creating new revenue opportunities. Q3. Which therapy segments lead this market? A3. Chemotherapy leads with a 34% share and USD 1.751 billion in 2025 revenue. Immunotherapy represents the fastest-growing segment, expanding at a CAGR of 15.10% as pembrolizumab, nivolumab, and combination regimens gain wider clinical use. Q4. How is biomarker testing changing this industry? A4. Biomarker testing helps identify patients suitable for HER2-targeted therapies, immune checkpoint inhibitors, antibody-drug conjugates, and emerging Claudin 18.2 or FGFR2b treatments. This selection process is moving treatment value from broad chemotherapy toward precision oncology. Q5. Which drug class is expanding fastest in this market? A5. PD-1/PD-L1 immune checkpoint inhibitors are the fastest-growing drug class. The segment generated approximately USD 1.133 billion in 2025 and is projected to expand at a CAGR of 16.25% during 2026–2032. Q6. Which treatment facilities dominate this market? A6. Hospitals and comprehensive cancer centers lead with a 78% share and USD 4.017 billion in 2025 revenue. Their position reflects the need for surgery, pathology, molecular diagnostics, intravenous treatment, and multidisciplinary oncology care within the same clinical setting. Q7. Which region leads this market? A7. Asia-Pacific leads with a 38% share and approximately USD 1.957 billion in 2025 revenue. It is also the fastest-growing region, with a projected CAGR of 12.85%, due to the high disease burden in China, Japan, and South Korea. Q8. Which companies are shaping competition in this industry? A8. Merck, Bristol Myers Squibb, AstraZeneca, Daiichi Sankyo, Roche, Astellas Pharma, Amgen, Eli Lilly, Pfizer, BeiGene, and Zymeworks are prominent participants. Competition is focused on immunotherapy combinations, HER2-directed medicines, antibody-drug conjugates, and biomarker-selected treatments. Sources: Disease Burden and Treatment Standards IARC Global Cancer Observatory — Stomach Cancer Fact Sheet National Cancer Institute — Gastric Cancer Treatment, Health Professional Version National Cancer Institute — Stomach Cancer Treatment Overview National Cancer Institute — Gastrointestinal Stromal Tumors Treatment National Cancer Institute — Gastrointestinal Neuroendocrine Tumors Treatment Immunotherapy Approvals FDA — Pembrolizumab With Chemotherapy for HER2-Negative Gastric or GEJ Cancer FDA — Pembrolizumab for HER2-Positive, PD-L1-Positive Gastric or GEJ Cancer FDA — Nivolumab Gastric and Gastroesophageal Cancer Approval Record FDA — Tislelizumab Prescribing Information Targeted Therapies and Biomarkers FDA — Enhertu for HER2-Positive Gastric Adenocarcinoma FDA — Vyloy for CLDN18.2-Positive Gastric or GEJ Cancer FDA — Cyramza for Advanced Gastric or GEJ Adenocarcinoma National Cancer Institute — Trastuzumab and HER2-Targeted Treatment ClinicalTrials.gov — FORTITUDE-101 Bemarituzumab Phase III Trial ClinicalTrials.gov — HERIZON-GEA-01 Zanidatamab Phase III Trial FDA — Zanidatamab and Tislelizumab for HER2-Positive Gastric, GEJ, or Esophageal Adenocarcinoma Company and Commercial Evidence Merck — 2025 Full-Year Results and Keytruda Sales Merck — 2025 Form 10-K Daiichi Sankyo — FY2025 Financial Results Daiichi Sankyo — FY2025 Results and Business Plan Presentation Daiichi Sankyo — FY2025 Investor Results Library Table of Contents - Global Gastric Cancer Therapeutics Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Therapy Type, Drug Class, Disease Indication, Route of Administration, End User, and Geography Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Therapy Type, Drug Class, Disease Indication, Route of Administration, End User, and Geography Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Therapy Type, Drug Class, Disease Indication, Route of Administration, and End User Investment Opportunities in the Gastric Cancer Therapeutics Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Immunotherapy Combinations, Biomarker-Driven Targeted Therapies, Antibody-Drug Conjugates, Claudin 18.2-Directed Treatments, FGFR2-Directed Treatments, and Precision Oncology Programs Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Gastric Cancer Therapeutics in Biomarker-Driven Oncology and Personalized Treatment Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory and Clinical Development Factors Role of Immunotherapy Combinations, Targeted Therapies, Antibody-Drug Conjugates, and Molecular Testing in Market Expansion Biomarker Selection, Precision Oncology, Treatment Personalization, and Diagnostic-Therapeutic Integration Trends Global Gastric Cancer Therapeutics Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Therapy Type: Chemotherapy Targeted Therapy Immunotherapy Radiation Therapy and Supportive Care Market Analysis by Drug Class: Cytotoxic Agents HER2-Targeted Therapies and Antibody-Drug Conjugates (ADCs) PD-1/PD-L1 Immune Checkpoint Inhibitors VEGF, FGFR2, Claudin 18.2, and Other Targeted Agents Market Analysis by Disease Indication: Gastric Adenocarcinoma and Gastroesophageal Junction (GEJ) Cancer Gastrointestinal Stromal Tumors (GISTs) Gastric Neuroendocrine Tumors (gNETs) and Other Rare Gastric Tumors Market Analysis by Route of Administration: Intravenous (IV) Therapies Oral Therapies Market Analysis by End User: Hospitals and Comprehensive Cancer Centers Specialty Oncology Clinics Research Institutes and Other Healthcare Facilities Market Analysis by Geography: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Gastric Cancer Therapeutics Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Therapy Type, Drug Class, Disease Indication, Route of Administration, and End User Country-Level Breakdown: United States Canada Mexico Europe Gastric Cancer Therapeutics Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Therapy Type, Drug Class, Disease Indication, Route of Administration, and End User Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Gastric Cancer Therapeutics Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Therapy Type, Drug Class, Disease Indication, Route of Administration, and End User Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Gastric Cancer Therapeutics Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Therapy Type, Drug Class, Disease Indication, Route of Administration, and End User Country-Level Breakdown: Brazil Argentina Rest of Latin America Middle East & Africa Gastric Cancer Therapeutics Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Therapy Type, Drug Class, Disease Indication, Route of Administration, and End User Country-Level Breakdown: GCC Countries South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Merck & Co. Bristol Myers Squibb AstraZeneca Daiichi Sankyo Company, Limited F. Hoffmann-La Roche Ltd. Astellas Pharma Inc. Amgen Inc. Eli Lilly and Company Pfizer Inc. BeiGene Ltd. Zymeworks Inc. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Innovent Biologics, Inc. Zai Lab Limited Merck KGaA Competitive Landscape and Strategic Insights Benchmarking Based on Biomarker Coverage, Clinical Development Strength, Targeted Therapy Portfolio, Immuno-Oncology Capabilities, Antibody-Drug Conjugate Development, and Regional Presence Precision Oncology and Molecular Testing Capability Analysis HER2-Directed Therapy Positioning PD-1/PD-L1 Immunotherapy and Combination Treatment Competitiveness Antibody-Drug Conjugates, Claudin 18.2, FGFR2, and Other Targeted Treatment Strategy Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Therapy Type, Drug Class, Disease Indication, Route of Administration, End User, and Geography (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading Vendors Biomarker Testing, Treatment Selection, and Precision Oncology Analysis Therapy Adoption Trends Across Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy and Supportive Care List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Therapy Type, Drug Class, Disease Indication, Route of Administration, and End User (2025 vs. 2032) Global Gastric Cancer Therapeutics Ecosystem and Value Chain Analysis